This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rochester Medical Discusses Q2 2011 Results -- Earnings Call Transcript

Rochester Medical Corporation ( ROCM)

Q2 2011 Earnings Call

July 28, 2011, 04:30 pm ET


Anthony Conway - Chairman, CEO & President

Dave Jonas - Director, CFO & Secretary


Ernest Andberg - Feltl & Company

Tyson Bauer - Wealth Monitors

Elizabeth Lilly - Gabelli



Good day ladies and gentlemen and welcome to the third quarter 2011 Rochester Medical Corporation earnings conference call. My name is Melanie and I would be your coordinator today. At this time all participants are in listen-only mode. We will accept your questions at the end of today's conference. (Operator's Instructions). As a reminder today's call is being recorded.

I would now like to turn the call over to Mr. Anthony Conway, President and CEO. Please proceed sir.

Anthony Conway

Hi everyone. Thank you for joining Rochester Medical’s third quarter conference call. I am Anthony Conway, the Company's President and CEO. And with me is Dave Jonas, Rochester Medical’s Chief Financial Officer.

First I will provide a high level review of our third quarter. Dave will then provide you with more details on our financial results and then I will give a quick update on a few items and summarize. And then we will take your questions.

Before starting let me remind you that we will be making some forward-looking statements today and I would refer you to the Safe Harbor statement found in today's press release and also to the risk factors section in the Company's annual report on Form 10-K for the year ended September 30, 2010. These statements further clarify the risks and uncertainties that are associated with the forward-looking statements.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs